AstraZeneca 과거 순이익 실적

과거 기준 점검 5/6

AstraZeneca은 연평균 32.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 8.6% 증가했습니다. 매출은 연평균 14.2%의 비율로 증가했습니다. AstraZeneca의 자기자본이익률은 20.5%이고 순이익률은 16.2%입니다.

핵심 정보

32.76%

순이익 성장률

29.53%

주당순이익(EPS) 성장률

Pharmaceuticals 산업 성장률	5.95%
매출 성장률	14.23%
자기자본이익률	20.46%
순이익률	16.17%
다음 순이익 업데이트	10 Feb 2026

최근 과거 실적 업데이트

Recent updates

매출 및 비용 세부 내역

AstraZeneca가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGS:AZN 매출, 비용 및 순이익 (USD Millions)
날짜	매출	순이익	일반관리비	연구개발비
30 Sep 25	58,127	9,399	19,228	13,573
30 Jun 25	56,501	8,295	19,320	13,058
31 Mar 25	54,982	7,772	19,397	12,559
31 Dec 24	54,073	7,035	19,453	12,243
30 Sep 24	51,206	6,495	18,765	11,793
30 Jun 24	49,133	6,440	18,406	11,206
31 Mar 24	47,611	6,331	18,462	10,816
31 Dec 23	45,811	5,955	18,025	10,373
30 Sep 23	44,994	5,896	18,258	9,922
30 Jun 23	44,485	6,163	17,732	9,782
31 Mar 23	43,840	4,705	17,425	9,642
31 Dec 22	44,351	3,288	17,460	9,669
30 Sep 22	45,155	2,040	17,425	9,134
30 Jun 22	44,038	-1,253	17,232	9,184
31 Mar 22	41,487	-1,063	15,623	8,535
31 Dec 21	37,417	112	14,673	8,049
30 Sep 21	32,816	1,471	13,651	7,831
30 Jun 21	29,528	3,771	12,270	6,888
31 Mar 21	27,583	3,977	11,808	6,448
31 Dec 20	26,617	3,196	11,586	5,901
30 Sep 20	25,871	2,497	10,909	5,653
30 Jun 20	25,699	2,148	11,367	5,504
31 Mar 20	25,247	1,522	11,652	5,471
31 Dec 19	24,384	1,335	11,438	5,349
30 Sep 19	24,137	2,056	12,134	5,442
30 Jun 19	23,071	2,188	11,317	5,338
31 Mar 19	22,403	2,408	10,880	5,313
31 Dec 18	22,090	2,155	10,822	5,299
30 Sep 18	21,450	2,422	9,850	5,251
30 Jun 18	22,342	2,677	9,885	5,378
31 Mar 18	22,238	2,804	9,625	5,358
31 Dec 17	22,465	3,001	9,406	5,455
30 Sep 17	22,273	3,542	9,251	5,507
30 Jun 17	21,740	3,870	9,049	5,501
31 Mar 17	22,292	3,390	9,645	5,586
31 Dec 16	23,002	3,499	9,743	5,679
30 Sep 16	23,816	2,465	10,464	5,790
30 Jun 16	24,062	2,221	10,784	5,800
31 Mar 16	24,766	2,921	10,796	5,808
31 Dec 15	24,708	2,825	11,024	5,660
30 Sep 15	25,025	1,696	11,796	5,392
30 Jun 15	25,689	1,180	12,255	5,361
31 Mar 15	26,144	1,279	12,280	5,180

양질의 수익: AZN는 $3.2B 규모의 큰 일회성 손실이 있어 30th September, 2025까지 지난 12개월 재무 결과에 영향을 미쳤습니다.

이익 마진 증가: AZN의 현재 순 이익률 (16.2%)은 지난해 (12.7%)보다 높습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: AZN의 수익은 지난 5년 동안 연평균 32.8%로 크게 증가했습니다.

성장 가속화: 지난 1년간 AZN 의 수익 증가율(44.7%)은 연간 평균(32.8%)을 초과합니다.

수익 대 산업: AZN의 지난 1년 수익 증가율(44.7%)은 Pharmaceuticals 업계의 14.9%를 상회했습니다.

자기자본이익률

높은 ROE: AZN의 자본 수익률(20.5%)은 높음으로 평가됩니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/01 09:17
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

AstraZeneca PLC는 62명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
null null	ABG Sundal Collier
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

AstraZeneca 과거 순이익 실적

과거 기준 점검 5/6

핵심 정보

최근 과거 실적 업데이트

AstraZeneca PLC to Report Q2, 2025 Results on Jul 29, 2025

Recent updates

Astrazeneca and Enhertu Announce that it has Been Granted Breakthrough Therapy Designation in the US for Adult Patients with Her2-Positive Early Breast Cancer with Residual Invasive Disease in the Breast And/Or Axillary Lymph Nodes After Neoadjuvant Treatment and High Risk of Disease Recurrence

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

AstraZeneca PLC Advances Hematology and Cell Therapy Ambition with Largest-Ever Presence at ASH

AstraZeneca's New Drug Application Accepted Under FDA Priority Review in the US for Patients with Hard-To-Control Hypertension

AstraZeneca plc Announces Approval in the US for First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) Approves in the US

AstraZeneca Announces Positive Full Results from the Bax24 Phase III Trial

AstraZeneca PLC Reiterates Earnings Guidance for 2025

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

AstraZeneca PLC Announces Koselugo Approved in the EUfor Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1

AstraZeneca and Amgen's Tezepelumab Approves in the European Union

Daiichi Sankyo and AstraZeneca Announces Positive Results from the TROPION-Breast02 Phase 3 Trial

AstraZeneca and Amgen's Tezepelumab Approves in the US for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca, Inc. Announces Positive Results from the Matterorn Phase III Trial

AstraZeneca Furthers ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO

AstraZeneca PLC Announces Baxdrostat Met Primary Endpoints in Bax24 Phase Iii Trial in Patients with Resistant Hypertension

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from Planned Interim Analysis of the DESTINY-Breast05 Phase III Trial

AstraZeneca Launches Direct-To-Consumer Platform to Expand Access to Medications for US Patients, Including Those Living with Chronic Conditions

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

AstraZeneca PLC Announces European Medicines Agency Recommends Koselugo for the Treatment of Plexiform Neurofibromas in Adult Patients

AstraZeneca, Inc. Provides Update on A Supplemental New Drug Application (sNDA) for Airscra

AstraZeneca plc Announces Saphnelo Met Primary Endpoint in TULIP-SC

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

AstraZeneca Announces Positive Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

AstraZeneca Launches FluMist Home, At-Home Delivery Service for FLUMIST

Astrazeneca Canada Inc. Announces Approval in Canada as First and Only Perioperative Immunotherapy for Muscle Invasive Bladder Cancer

AstraZeneca PLC Reiterates Earnings Guidance for the Fiscal Year 2025

AstraZeneca PLC Announces Positive Results from PrevaIL Phase III Trial

AstraZeneca Announces Positive High-Level Results from the Final Overall Survival Analysis of the FLAURA2 Phase III Trial

Alexion Announces Update on CARES Phase III Clinical Programme of Anselamimab in Light Chain Amyloidosis

AstraZeneca plc Announces Baxdrostat Met the Primary and All Secondary Endpoints in BaxHTN Phase III Trial in Patients with Undunded or Treatment Resistant Hypertension

European Union Approves Imfinzi®? (Durvalumab) for the Treatment of Adult Patients with Resistant Muscle-Invasive Bladder Cancer

Datroway Approves in Us for EGFRm Lung Cancer

AstraZeneca plc Announces Fixed-Term Calquence Approval in EU for 1L CLL

AstraZeneca and Daiichi Sankyo’S ENHERTU Plus Pertuzumab Showed A Median Progression-Free Survival Greater Than Three Years

Astrazeneca's Imfinzi Recommends for Approval in the Eu by Chmp as First and Only Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer

Health Canada Grants Notice of Compliance with Conditions for Tagrisso (Osimertinib) for the Treatment of Patients with Locally Advanced, Unresectable (Stage Iii) Non-Small Cell Lung Cancer

AstraZeneca 's Record Seventh Year of Plenary Data At Asco Furthers Ambition to Redefine Breast Cancer Care and Transform Outcomes in Gastric Cancer

AstraZeneca PLC (LSE:AZN) completed the acquisition of EsoBiotec B.V.

Astrazeneca to Showcase Latest Research on Comprehensive Portfolio and Pipeline Aimed At Transforming Respiratory Diseases At ATS 2025

AstraZeneca’s IMFINZI® (durvalumab) Regimen Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival for High-Risk Non-Muscle-Invasive Bladder Cancer in Potomac Phase III Trial

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the DESTINY-Breast11 Phase III Trial

Astrazeneca Met Primary Endpoints in Kalos and Logos Phase Iii Trials in Asthma

AstraZeneca PLC to Report Q2, 2025 Results on Jul 29, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

AstraZeneca PLC Appoints Karen Knudsen as Director

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC Approves Imfinzi in Eu for AEGEAN

AstraZeneca’s AZD0780 Demonstrates Significant LDL Cholesterol (LDL-C) Reduction in Pursuit Phase IIb Trial

IgniteData Advances Clinical Trial Efficiencies with Successful Deployment at Leading Cancer Center

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AstraZeneca PLC Announces Eneboparatide Met Primary Endpoint of Normalising Seric Calypso Trial Continues as Planned to 52 Weeks to Further Characterise the Risk-Benef Benefit Profile

Ionis Pharmaceuticals, Inc. and Astrazeneca’s WAINZUA (eplontersen) Approves in the EU for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy

AstraZeneca PLC Announces Positive High-Level Results from the Matterhorn Phase III Trial

AstraZeneca: A Big Pharma Blue Chip To Buy Now

AstraZeneca and Amgen's Tezepelumab-ekko Significantly Reduced Nasal Polyps

Daiichi Sankyo and AstraZeneca's Enhertu Recommends for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

AstraZeneca PLC Announces Positive High-Level Results from Planned Interim Analysis of SERENA-6 Phase III Trial

AstraZeneca PLC (LSE:AZN) agreed to acquire Beijing Fibrogen Medical Technology Development Co., Ltd. from FibroGen, Inc. (NasdaqGS:FGEN).

AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold

AstraZeneca PLC, Annual General Meeting, Apr 11, 2025

AstraZeneca PLC Announces Board and Committee Changes

Astrazeneca plc Provides Earning Guidance for the Fiscal Year 2025

Tropion-Lung12 Phase 3 Trial Initiated Evaluating Datroway as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer At High Risk of Relapse